This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study is to Assess Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Who Showed Unsuccessful Response to Existing Disease Modifying Antirheumatic Drugs (DMARDs) (TREASURE)

This study has been completed.
Astellas Pharma Korea, Inc.
Information provided by (Responsible Party):
Astellas Pharma Inc Identifier:
First received: January 4, 2012
Last updated: October 27, 2015
Last verified: October 2015
This study is to assess efficacy and safety of tacrolimus in active rheumatoid arthritis patients who showed unsuccessful response to existing DMARDs.

Condition Intervention Phase
Rheumatoid Arthritis Drug: Tacrolimus Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open- Label, Single-arm, Phase 4 Study to Assess the Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Shown Unsuccessful Response Against DMARDs

Resource links provided by NLM:

Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • ACR20 response rate 6 months post dose [ Time Frame: Baseline and 6 months post dose ]
    ACR20 is 20% improvement in ACR (American College of Rheumatology) core set

Secondary Outcome Measures:
  • ACR50 response rates at month 6 [ Time Frame: Baseline and at month 6 ]
    ACR50 is 50% improvement in ACR (American College of Rheumatology) core set

  • ACR70 response rates at month 6 [ Time Frame: Baseline and at month 6 ]
    ACR70 is 70% improvement in ACR (American College of Rheumatology) core set

  • Change in DAS28 from baseline to 6 months [ Time Frame: Baseline and at month 6 ]
    DAS (Disease Activity Score in Rheumatoid Arthritis)

  • Change in bone loss rate from baseline to 6 months [ Time Frame: Baseline and at month 6 ]
    comparative factors for bone loss rate: bone mineral densitometry [BMD], bone turnover marker test

  • Safety assessed by the incidence of adverse events, vital signs and lab-tests [ Time Frame: For 6 months ]

Enrollment: 128
Study Start Date: December 2011
Study Completion Date: May 2015
Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tacrolimus group Drug: Tacrolimus
Other Name: Prograf


Ages Eligible for Study:   20 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects who have rheumatoid arthritis for 6 months or longer based on American College of Rheumatology (ACR) diagnostic criteria
  • Subjects who used more than 1 Disease Modifying Antirheumatic Drug (DMARD) including MTX (methotrexate) for 6 months or longer
  • Subjects with ESR (erythrocyte sedimentation rate) ≥ 28mm/h or CRP (C-reactive protein)≥ 1.0 mg/dL
  • Subjects with ≥ 3 swollen joints out of 66 joints assessed
  • Subjects with ≥ 6 tender joints out of 68 joints assessed
  • Subjects with BMD (bone mineral densitometry) ≤ -3.0

Exclusion Criteria:

  • Pregnant or nursing women, or subjects who plan to become pregnant within 6 months or whose screening test results show pregnancy cannot be ruled out
  • Subjects with previous experience of tacrolimus (excluding external preparations)
  • Subjects with renal dysfunction or with serum creatinin > 1.4 mg/dL at screening
  • Following subjects with hepatic dysfunction: viral infection, non-viral infection, hepatic cirrhosis, and Serum Glutamic Oxaloacetic Transaminase / Serum Glutamic Pyruvic Transaminase (SGOT/SGPT) exceeding twice the upper limit of normal at screening
  • Subjects with pancreatitis, uncontrolled diabetes or complication(s) or with HbA1c > 6.4% at screening
  • Subjects complicated with hyperkalemia or with serum potassium level >5.5 mEq/L at screening
  • Subjects with history of heart disease (ischemic heart disease, arrhythmia requiring treatment, and heart failure), etc or complications
  • Subjects complicated with severe respiratory disease and infection
  • Subjects with history of malignant tumor or complication(s) (However, the subjects who are considered to have no risk of recurrence with malignant tumor untreated for 5 years or longer can enter the study. The subjects who succeeded in treatment for basal cell or squamous cell carcinoma of skin can also enter the study.)
  • Subjects who were treated with other investigational product(s) within 3 months before screening
  • Other subjects who are considered ineligible for the study by the investigator
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01511003

Korea, Republic of
Busan, Korea, Republic of
Daejeon, Korea, Republic of
Gyeonggi-do, Korea, Republic of
Seoul, Korea, Republic of
Sponsors and Collaborators
Astellas Pharma Inc
Astellas Pharma Korea, Inc.
Study Chair: Use Central Contact Astellas Pharma Inc
  More Information

Responsible Party: Astellas Pharma Inc Identifier: NCT01511003     History of Changes
Other Study ID Numbers: PRGRA-10-04-KOR
Study First Received: January 4, 2012
Last Updated: October 27, 2015

Keywords provided by Astellas Pharma Inc:
calcineurin inhibitor
Rheumatoid arthritis (RA)

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Antirheumatic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on June 23, 2017